U.S. FDA approves Amylyx ALS drug

(Reuters) – The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc’s drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

(Reporting by Leroy Leo in Bengaluru; editing by Caroline Humer and Bill Berkrot)